Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 571 to 585 of 1300 results for heart OR cardi* OR arrythmia

  1. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

  2. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

  3. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

  4. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

  5. Hemosep for cell salvage (MIB103)

    NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .

  6. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

  7. Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care (CG5)

    This guideline has been updated and replaced by NICE guideline CG108.

  8. Lactate level for monitoring severity of shock:- Is lactate monitoring in patients with major trauma clinically and cost effective?

    hypovolaemic shock is guided by the patient's haemodynamic levels, including heart rate and blood pressure. However, haemodynamic levels...

  9. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  10. Diabetes: T1DM and lipid-lowering therapies (IND277)

    This indicator covers the percentage of patients with type 1 diabetes aged over 40 years (excluding people with a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  11. National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)

    NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .

  12. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  13. Does early review of service provision and referral to additional specialist palliative care services improve outcomes for adults with progressive non-cancer disease thought to be approaching the end of their life?

    for example in patients with progressive organ failure, such as advanced heart failure, or patients with life-limiting neurological...

  14. Major trauma: assessment and initial management (NG39)

    This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.